Bayer Schering news from FierceBiotech
NewsBayer strikes deal for Nycomed cancer therapies
A Swiss company's decision to drop its cancer programs will help Bayer beef up its oncology pipeline. Bayer has agreed to buy Nycomed's preclinical cancer therapies in a deal worth up to €52 Read more...
CHMP recommends Bayer's Xarelto
Among a number of CHMP announced today was the committee's recommendation of Bayer's Xarelto, known generically as rivaroxaban. Xarelto, a blood-thinning pill to prevent clots in patients bedridden Read more...
Bayer dumps Titan drug on mid-stage failure
Titan Pharmaceuticals announced this morning that its Parkinson's drug Spheramine failed to hit primary and secondary endpoints in a Phase IIb trial for moderate to advanced Parkinson's disease. Read more...
Maxygen inks $120M deal for hemophilia program
Maxygen has inked a deal to sell its hemophilia drug development program to Bayer for $90 million upfront and up to $30 million in milestone payments. The program is still in the preclinical stage, Read more...
Bayer, J&J tout rivaroxaban data
In a head-to-head study against Sanofi's Lovenox, Bayer and J&J's oral anti-clotting drug rivaroxaban proved superior in preventing venous blood clots in patients who underwent total knee Read more...
ALSO NOTED: Arqule hires new CEO; Kosan launches mid-stage study; and much more...
> Is the U.S. drug industry bargain-basement land right now? Analysts say that the low, low dollar means low, low prices for pharma companies. Rivals in Asia and the Eurozone could snap up drug Read more...
Onyx shares tumble after Nexavar failure
The Motley Fool has been counting the casualties since Onyx and Bayer halted their trial for Nexavar as a therapy for non-small cell lung cancer. Onyx's stock has shed 31 percent of its value since Read more...
Nexavar failure raises questions for developers
Shares of Onyx Pharmaceuticals tanked on disappointing data from its latest cancer trial of Nexavar as a therapy for non-small cell lung cancer. With no hope of seeing data that patients lives were Read more...
Dara BioSciences goes public in reverse merger
Dara BioSciences has completed a reverse merger with the nearly-defunct Point Therapeutics, Read more...
Cell Therapeutics reorganizes, scales back R&D
Cell Therapeutics is scaling back its research plans for Xyotax and pixantrone, cutting one group of Read more...
| Press ReleasesPRESS RELEASE: Major Phase 3 Trial Shows Zevalin Extends Progression-free Survival in One of the Most Common Types of Lymphoma
Major Phase 3 Trial Shows Zevalin Extends Progression-free Survival in One of the Most Common Types of Lymphoma
Zevalin® Phase 3 Multi-National Read more... PRESS RELEASE: BEYOND study: Results do not support regulatory filing for Betaferon® 500 mcg BEYOND study: Results do not support regulatory filing for Betaferon® 500 mcg Betaferon® 250 mcg is optimal Betaferon® dose based on high efficacy and excellent tolerability / Study unable to Read more... PRESS RELEASE: DARA BioSciences and Bayer Pharmaceuticals Corporation Sign Exclusive License Agreement DARA BioSciences and Bayer Pharmaceuticals Corporation Sign Exclusive License Agreement RALEIGH, N.C. and WEST HAVEN, Conn., Oct. 17 -- DARA BioSciences, Inc. and Bayer Pharmaceuticals Corporation Read more... PRESS RELEASE: Genzyme and Bayer Schering Pharma, Germany Announce Start of Phase 3 Program with Alemtuzumab Genzyme and Bayer Schering Pharma, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis CAMBRIDGE, Mass., and BERLIN, Sept. 26 -- Genzyme Corporation and Read more... PRESS RELEASE: FDA Approves Expanded Labeling for Campath FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia Study data demonstrated improved progression-free survival with Campath Berlin, Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets